OBJECTIVE: To evaluate the clinical comprehensive value of N-acetylcysteine effervescent tablets in the treatment of chronic obstructive pulmonary disease（COPD）

so as to provide evidence for decision-making at all levels and to better guide clinical practice. METHODS: Domestic and foreign literature/abstract databases were searched

and evidence-based medical evidence such as clinical diagnosis and treatment guidelines（including expert consensus）

systematic reviews/Meta-analysis and randomized controlled trials were included. Drug instructions

prices

procurement and consumption sum were obtained from drug manufacturers and third-party drug market databases. Safety

efficacy

economy

innovation

suitability

and accessibility of N-acetylcysteine effervescent tablets in the treatment of COPD were qualitatively and quantitatively evaluated according to the Guidelines for Comprehensive Clinical Evaluation of Drugs（Trial Version 2021）. RESULTS: A total of 1 746 articles were obtained from the primary screening

22 studies were finally included in the systematic review/Meta-analysis. In terms of efficacy and safety

N-acetylcysteine effervescence tablets could improve the pulmonary function

blood gas analysis and other clinical efficacy outcome indicators of COPD

and the overall incidence of adverse events was similar to that of placebo or blank control

and no severe adverse events were observed. In terms of economy

it was more economical to use N-acetylcysteine effervescent tablets on the basis of conventional treatment in the treatment of acute exacerbation of COPD. N-acetylcysteine effervescent tablets were innovative in terms of preparation

which was more conducive to patients with difficulty in swallowing or sensitive to odor. The price level

affordability and availability of N-acetylcysteine effervescent tablets were good. CONCLUSIONS: For patients with COPD

N-acetylcysteine effervescent tablets have good clinical application value.